A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Roflumilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Acronyms DERMIS-OLE
- Sponsors Arcutis Biotherapeutics
Most Recent Events
- 05 Mar 2024 Status changed from active, no longer recruiting to completed.
- 11 Sep 2023 Planned End Date changed from 1 Sep 2023 to 26 Jan 2024.
- 11 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 26 Jan 2024.